Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has shared an update.
On May 12, 2025, Apimeds Pharmaceuticals US, Inc. successfully completed its initial public offering (IPO) of 3,375,000 shares of common stock at $4.00 per share, raising $13.5 million in gross proceeds. The shares began trading on the NYSE American under the symbol ‘APUS’ on May 9, 2025. The company plans to use the proceeds to fund a Phase III clinical trial for knee osteoarthritis, initiate a study in multiple sclerosis, manufacture its product candidate, and address general working capital needs. The IPO also involved the conversion of convertible promissory notes into common stock, further consolidating the company’s financial structure.
More about Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company focused on developing Apitox, an intradermally administered bee venom-based toxin. The company is targeting the treatment of osteoarthritis, particularly for patients with knee pain who do not respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Average Trading Volume: 1,682,063
Find detailed analytics on APUS stock on TipRanks’ Stock Analysis page.